Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: JDN who wrote (3239)	8/24/1999 4:31:00 PM
From: BelowTheCrowd	Read Replies (2) \| Respond to of 10293

Nope, What counts is whether it SELLS. If it don't sell. GUMM will never get another order and depending on the distrubution agreements, may even need to take product back. If it sells, THEN they'll have an earnings stream, and may be evaluated on the merits of their ability to derive actual profits from the sales. Either way, my best observation is that they're toast, but I will be the first to admit that I haven't looked at this one much. I don't have a postion either way. mg

To: JDN who wrote (3239)	8/24/1999 6:57:00 PM
From: BDR	Read Replies (1) \| Respond to of 10293

Yup. Actually sales will count more than just the mere presence, but sales can occur despite the absence of scientific support for efficacy if the marketing is slick enough. I am only posting the fact that publication has not occurred yet because for a while the longs were repeatedly bringing up the mere submission of the article to the NEJM as evidence of the legitimacy of the product. Lack of publication may not cause the product to fail. Publication, especially if accompanied by a supportive editorial, will greatly increase sales.